News -
Stock Information
Relmada Therapeutics is dedicated to reshaping the standard of care for central nervous system disorders.
Our lead program, REL-1017, is a novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. REL-1017 is in advanced clinical development for the treatment of major depressive disorder (MDD).
Data from the Phase 2 trial with REL-1017 suggest rapid, robust, and sustained antidepressant effects with statistically significant improvements as compared to placebo on all tested efficacy measures (Fava 2022). The Phase 2 study data also confirm the very favorable safety and tolerability profile of REL-1017 seen in Phase 1 studies (Bernstein 2019). The U.S. Food and Drug Administration has granted Fast Track designations to REL-1017 for the treatment of MDD. The Phase 3 Reliance clinical trial program is underway with Reliance II and Reliance OLS ongoing and an expected initiation of additional clinical evaluations.
News
View all newsEvents
View all eventsEvent - Aug 8, 2023 4:30 PM EDT
Q2 2023 Financial Results Conference Call
Read moreEvent - Jun 14, 2023 6:20 PM EDT
Goldman Sachs Global Healthcare Conference
Read moreEvent - Jun 8, 2023 3:00 PM EDT
2023 Jefferies Global Healthcare Conference
Read moreEvent - May 30 – Jun 2, 2023
American Society of Clinical Psychopharmacology 2023 Annual Meeting
Event - May 25, 2023 9:30 AM EDT
2023 Annual Meeting of Stockholders
Read moreEvent - May 11, 2023 4:30 PM EDT
Q1 2023 Financial Results Conference Call
Read moreEvent - Mar 23, 2023 4:30 PM EDT
Q4 2022 Financial Results Conference Call
Read moreEvent - Nov 10, 2022 4:30 PM EDT